Cargando…
Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India
Today, drug safety data collection in India is both manual and electronic with reporting of potential overlapping and duplicate data, which is likely incomplete for further review and analysis. Furthermore, standardized data collection and timelines are not aligned with international standards. Comp...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384402/ https://www.ncbi.nlm.nih.gov/pubmed/28447016 http://dx.doi.org/10.4103/2229-3485.203046 |
_version_ | 1782520455854292992 |
---|---|
author | Harugeri, Anand Shastri, Vineet Patel, Chanakya |
author_facet | Harugeri, Anand Shastri, Vineet Patel, Chanakya |
author_sort | Harugeri, Anand |
collection | PubMed |
description | Today, drug safety data collection in India is both manual and electronic with reporting of potential overlapping and duplicate data, which is likely incomplete for further review and analysis. Furthermore, standardized data collection and timelines are not aligned with international standards. Complete coverage of safety data from all sources throughout the life of the drug cannot be ensured. There is no requirement to submit periodic safety data in clinical trials to regulatory authority. There is clearly a lack of emphasis on deriving meaningful safety data insights for ensuring patient safety. Efforts toward the early detection of drug safety issues are minimal. There is no mandate to publicly disclose drug safety findings. Benefit-risk evaluation of investigational and marketed products cannot be assured merely through annual status reports and periodic safety update reports, respectively. Focused initiatives involving stakeholders from regulatory, health-care, and pharmaceutical industries are required to change the current situation and enable derivation of meaningful insights from safety data. Equal emphasis on assessing real-time safety of the drugs and protection of patients' rights, safety, and well-being is required. Periodic safety data reporting in clinical trials, proactive safety data collection related to potential safety concerns, electronic medical records, electronic expedited reporting, collection of targeted data from stakeholders, and standardized and harmonized data collection aligned to the International Council for Harmonization guidelines are required. The Central Drugs Standard Control Organization should implement requirements to submit Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, and Risk Management Plans. Access to clinical trials and postmarketing safety data through central repository would enable researchers to explore the data for application in clinical practice. |
format | Online Article Text |
id | pubmed-5384402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-53844022017-04-26 Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India Harugeri, Anand Shastri, Vineet Patel, Chanakya Perspect Clin Res Review Article Today, drug safety data collection in India is both manual and electronic with reporting of potential overlapping and duplicate data, which is likely incomplete for further review and analysis. Furthermore, standardized data collection and timelines are not aligned with international standards. Complete coverage of safety data from all sources throughout the life of the drug cannot be ensured. There is no requirement to submit periodic safety data in clinical trials to regulatory authority. There is clearly a lack of emphasis on deriving meaningful safety data insights for ensuring patient safety. Efforts toward the early detection of drug safety issues are minimal. There is no mandate to publicly disclose drug safety findings. Benefit-risk evaluation of investigational and marketed products cannot be assured merely through annual status reports and periodic safety update reports, respectively. Focused initiatives involving stakeholders from regulatory, health-care, and pharmaceutical industries are required to change the current situation and enable derivation of meaningful insights from safety data. Equal emphasis on assessing real-time safety of the drugs and protection of patients' rights, safety, and well-being is required. Periodic safety data reporting in clinical trials, proactive safety data collection related to potential safety concerns, electronic medical records, electronic expedited reporting, collection of targeted data from stakeholders, and standardized and harmonized data collection aligned to the International Council for Harmonization guidelines are required. The Central Drugs Standard Control Organization should implement requirements to submit Development Safety Update Reports, Periodic Benefit-Risk Evaluation Reports, and Risk Management Plans. Access to clinical trials and postmarketing safety data through central repository would enable researchers to explore the data for application in clinical practice. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5384402/ /pubmed/28447016 http://dx.doi.org/10.4103/2229-3485.203046 Text en Copyright: © 2017 Perspectives in Clinical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Harugeri, Anand Shastri, Vineet Patel, Chanakya Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title | Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title_full | Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title_fullStr | Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title_full_unstemmed | Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title_short | Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India |
title_sort | deriving meaningful insights from clinical trial and postmarketing safety data: perspectives from india |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384402/ https://www.ncbi.nlm.nih.gov/pubmed/28447016 http://dx.doi.org/10.4103/2229-3485.203046 |
work_keys_str_mv | AT harugerianand derivingmeaningfulinsightsfromclinicaltrialandpostmarketingsafetydataperspectivesfromindia AT shastrivineet derivingmeaningfulinsightsfromclinicaltrialandpostmarketingsafetydataperspectivesfromindia AT patelchanakya derivingmeaningfulinsightsfromclinicaltrialandpostmarketingsafetydataperspectivesfromindia |